NasdaqGS - Nasdaq Real Time Price USD

Alkermes plc (ALKS)

Compare

28.08

-0.34

(-1.20%)

At close: January 10 at 4:00:01 PM EST

28.08

0.00

(0.00%)

After hours: January 10 at 5:03:39 PM EST

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

Investor's Business Daily 4 days ago

ALKS
-1.20%
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

PR Newswire 10 days ago

ALKS
-1.20%
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)?

With its stock down 2.4% over the past week, it is easy to disregard Alkermes (NASDAQ:ALKS). However, stock prices are...

Simply Wall St. 12 days ago

ALKS
-1.20%
Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

QGEN

ALKS
-1.20%
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

ALKS
-1.20%
Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

ILMN

ALKS
-1.20%
Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

ALKS
-1.20%
Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

INCY
-3.54%
ALKS
-1.20%
Axsome Therapeutics eyes approval after Phase III narcolepsy win

The company’s Phase III trial of AXS-12 showed results over placebo as the company looks towards filing a new drug application for its narcolepsy therapy.

Clinical Trials Arena last month

ALKS
-1.20%
Alkermes to Participate in Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.

PR Newswire last month

ALKS
-1.20%
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

Zacks last month

ALKS
-1.20%
Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences.

PR Newswire 2 months ago

ALKS
-1.20%
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston, and the

PR Newswire 2 months ago

ALKS
-1.20%
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.

Zacks 2 months ago

ALKS
-1.20%
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations

Alkermes ( NASDAQ:ALKS ) Third Quarter 2024 Results Key Financial Results Revenue: US$378.1m (flat on 3Q 2023). Net...

Simply Wall St. 2 months ago

ALKS
-1.20%
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...

Alkermes PLC (ALKS) reports robust revenue growth driven by Vivitrol and Lybalvi, while navigating market challenges and investing in future opportunities.

GuruFocus.com 2 months ago

ALKS
-1.20%
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 2 months ago

ALKS
-1.20%
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of -6.41% and 2.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ALKS
-1.20%
Alkermes: Q3 Earnings Snapshot

DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported third-quarter profit of $92.4 million. On a per-share basis, the Dublin-based company said it had profit of 55 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 73 cents per share.

Associated Press Finance 2 months ago

ALKS
-1.20%
Alkermes plc Reports Third Quarter 2024 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024.

PR Newswire 2 months ago

ALKS
-1.20%

Performance Overview

Return	ALKS	S&P 500
YTD	-2.43%	-1.35%
1-Year	-3.11%	+22.51%
3-Year	+16.95%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alkermes plc (ALKS)

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)?

Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Axsome Therapeutics eyes approval after Phase III narcolepsy win

Alkermes to Participate in Upcoming Investor Conferences

Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates

Alkermes: Q3 Earnings Snapshot

Alkermes plc Reports Third Quarter 2024 Financial Results

Performance Overview